RxDoctor Payments Data

Matthew Grove, DO

Interventional Cardiology · New Bern, NCNPI 1841322260

Payments from drug & device makers

$5,770in general payments, 2019–2025

Across 382 payments — averaging $15.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$822
  • E.r. Squibb & Sons, L.L.C.$814
  • Actelion Pharmaceuticals US, Inc.$686
  • Abbott$339
  • Merck$296
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$277
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$5,72499%
  • Education$461%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,770 in reported general payments places this provider in the 35th percentile of 180 interventional cardiology providers in North Carolina.

See all interventional cardiology providers in North Carolina

Medicare billing

Part B allowed, 2024
$596,255
Medicare patients
2,014
Services billed
7,463

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban587$537,811
EntrestoSacubitril/Valsartan232$240,859
XareltoRivaroxaban147$107,601
Repatha SureclickEvolocumab117$77,805
FarxigaDapagliflozin Propanediol37$37,138
Dofetilide117$21,685
JardianceEmpagliflozin16$15,034
Dabigatran EtexilateDabigatran Etexilate Mesylate58$13,683
Ranolazine ErRanolazine174$9,859
NexlizetBempedoic Acid/Ezetimibe19$9,080
LivaloPitavastatin Calcium14$8,909
Metoprolol Succinate645$8,624
DapagliflozinDapagliflozin Propanediol11$6,459
BenicarOlmesartan Medoxomil11$5,383
Valsartan227$4,991

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$163$537,811587 claims
NovartisEntresto$822$240,859232 claims
Johnson & JohnsonXarelto$214$107,601147 claims
AstraZenecaFarxiga$192$37,13837 claims
Boehringer IngelheimJardiance$109$15,03416 claims
Esperion Therapeutics, Inc.Nexlizet$133$9,08019 claims
Kowa Pharmaceuticals America, Inc.Livalo$28$8,90914 claims
Daiichi Sankyo Inc.Benicar$55$5,38311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 180 interventional cardiology providers in North Carolina.

Other interventional cardiology in New Bern

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →